Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06120504 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
A Phase 1 study, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06120504 is a Phase 1 study that was terminated before completion, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 22 participants.
The verdict
NCT06120504, a Phase 1 study, was terminated before completion, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infections. There are several types of lymphoma. This study will enroll people who have lymphoma, such as classical Hodgkin lymphoma, peripheral T-cell lymphoma including systemic anaplastic large cell lymphoma, diffuse large B-cell lymphoma, or some types of primary cutaneous lymphoma. This clinical trial uses a drug called PF-08046045/SGN-35T. The study drug is in testing and has not been approved for sale. This is the first time PF-08046045 will be used in people. The study drug will be given as an infusion through a vein. This study will test the safety of PF-08046045 in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for PF-08046045. Part C will use the dose found in parts A and B to find out how safe PF-08046045 is and if it works to treat select lymphomas.
Interventions
- DRUG PF-08046045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-02-29 |
| Est. Completion | 2025-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06120504
The ClinicalTrials.gov registry entry for NCT06120504 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-08046045 is the first listed.
NCT06120504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06120504 about?
NCT06120504 is a clinical study titled "A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers". This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infections. There are several types of lymphoma. This study will enroll people who have lymphoma, such as classical Hodgkin lymphoma, peripheral T-cell lymphoma including systemic anaplastic larg...
What is the current status of trial NCT06120504?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2024-02-29. Estimated completion is 2025-12-10.
What interventions are being tested in trial NCT06120504?
The interventions under investigation include: PF-08046045 (DRUG).
Who is sponsoring clinical trial NCT06120504?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.